07:57 AM EST, 02/23/2026 (MT Newswires) -- ADC Therapeutics ( ADCT ) said Monday it amended its royalty purchase agreement with HealthCare Royalty, lowering the change of control payment to $150 million from $750 million through the end of 2027, and subsequently to $200 million.

In exchange, HealthCare Royalty has been granted warrants to purchase about 9.8 million common shares at an exercise price of $3.81 per share. The warrants are exercisable until Dec. 31, 2030, and are subject to a lock-up through the end of 2027, ADC said.

The updated agreement is based on confidence in the long-term outlook of antibody drug conjugate Zynlonta, which treats relapsed or refractory large B-cell lymphoma, ADC said.

Shares of ADC Therapeutics ( ADCT ) were 1% higher in premarket trading.